Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
Key facts
- Where
- Omaha, Philadelphia, Portland, Salt Lake City, and Seattle, United StatesSee the 5 sites
Where in United States
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, United StatesContact: Bridget KramerTaking people
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PAPhiladelphia, United StatesContact: Criswell Lavery, MPHTaking people
- VA Portland Health Care System, Portland, ORPortland, United StatesContact: Alexandra BennettTaking people
- VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, United StatesContact: Jennifer GodinaTaking people
- VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesContact: Hannah BrubeckTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- VA Office of Research and Development
- Trial code
- NCT06887452
- Record updated
- 21 October 2026
- Original description
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.Read full original descriptionShow less
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.
Inclusion: US Veterans with physician-diagnosed; Documented hyperuricemia (SU > 6.8 milligrams per deciliter); Satisfy American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria; Report 1 or more flares in the prior 6 months; Receipt of a new urate-lowering therapy (ULT) prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria.
Exclusion: Any patient intolerant or unable to take urate-lowering therapies (allopurinol or febuxostat); Patients with a rheumatology encounter within the prior 3 months; Patients with a concomitant medication of azathioprine or 6-MPC (urate-lowering therapy contraindicated); Patients with stage IV/V Chronic Kidney Disease (CKD); Patients on an allopurinol dose > 300 or a Febuxostat dose > 40; Patients with a life expectancy < 12 months.